Selected research
Market Structure
Global Midostaurin Soft Capsules Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Midostaurin Soft Capsules market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Midostaurin Soft Capsules is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Midostaurin Soft Capsules is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Midostaurin Soft Capsules is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Midostaurin Soft Capsules is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Midostaurin Soft Capsules include Dr Reddys Laboratories, Glenmark Pharmaceuticals, Zydus, Novartis and Teva Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Midostaurin Soft Capsules market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Midostaurin Soft Capsules and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Midostaurin Soft Capsules sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Midostaurin Soft Capsules market size, projected growth trends, production technologies, key applications, and end-use industries.
Midostaurin Soft Capsules Segment by Company
Dr Reddys Laboratories
Glenmark Pharmaceuticals
Zydus
Novartis
Teva Pharmaceuticals
Midostaurin Soft Capsules Segment by Type
Original Drug
Generic Drug
Midostaurin Soft Capsules Segment by Application
Systemic Mastocytosis
Acute Myeloid Leukemia
Other
Midostaurin Soft Capsules Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Midostaurin Soft Capsules market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Midostaurin Soft Capsules and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Midostaurin Soft Capsules.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Midostaurin Soft Capsules market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Midostaurin Soft Capsules manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Midostaurin Soft Capsules in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Midostaurin Soft Capsules in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Original Drug
- Generic Drug
Applications
- Systemic Mastocytosis
- Acute Myeloid Leukemia
- Other
Companies covered
- Dr Reddys Laboratories
- Glenmark Pharmaceuticals
- Zydus
- Novartis
- Teva Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Midostaurin Soft Capsules Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Midostaurin Soft Capsules Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Midostaurin Soft Capsules Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Midostaurin Soft Capsules Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Midostaurin Soft Capsules Market Dynamics
- 2.1 Midostaurin Soft Capsules Industry Trends
- 2.2 Midostaurin Soft Capsules Industry Drivers
- 2.3 Midostaurin Soft Capsules Industry Opportunities and Challenges
- 2.4 Midostaurin Soft Capsules Industry Restraints
3 Midostaurin Soft Capsules Market by Manufacturers
- 3.1 Global Midostaurin Soft Capsules Revenue by Manufacturers (2021-2026)
- 3.2 Global Midostaurin Soft Capsules Sales by Manufacturers (2021-2026)
- 3.3 Global Midostaurin Soft Capsules Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Midostaurin Soft Capsules Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Midostaurin Soft Capsules Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Midostaurin Soft Capsules Manufacturers, Product Type & Application
- 3.7 Global Midostaurin Soft Capsules Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Midostaurin Soft Capsules Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Midostaurin Soft Capsules Players Market Share by Revenue in 2025
- 3.8.3 2025 Midostaurin Soft Capsules Tier 1, Tier 2, and Tier 3
4 Midostaurin Soft Capsules Market by Type
- 4.1 Midostaurin Soft Capsules Type Introduction
- 4.1.1 Original Drug
- 4.1.2 Generic Drug
- 4.2 Global Midostaurin Soft Capsules Sales by Type
- 4.2.1 Global Midostaurin Soft Capsules Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Midostaurin Soft Capsules Sales by Type (2021-2032)
- 4.2.3 Global Midostaurin Soft Capsules Sales Market Share by Type (2021-2032)
- 4.3 Global Midostaurin Soft Capsules Revenue by Type
- 4.3.1 Global Midostaurin Soft Capsules Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Midostaurin Soft Capsules Revenue by Type (2021-2032)
- 4.3.3 Global Midostaurin Soft Capsules Revenue Market Share by Type (2021-2032)
5 Midostaurin Soft Capsules Market by Application
- 5.1 Midostaurin Soft Capsules Application Introduction
- 5.1.1 Systemic Mastocytosis
- 5.1.2 Acute Myeloid Leukemia
- 5.1.3 Other
- 5.2 Global Midostaurin Soft Capsules Sales by Application
- 5.2.1 Global Midostaurin Soft Capsules Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Midostaurin Soft Capsules Sales by Application (2021-2032)
- 5.2.3 Global Midostaurin Soft Capsules Sales Market Share by Application (2021-2032)
- 5.3 Global Midostaurin Soft Capsules Revenue by Application
- 5.3.1 Global Midostaurin Soft Capsules Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Midostaurin Soft Capsules Revenue by Application (2021-2032)
- 5.3.3 Global Midostaurin Soft Capsules Revenue Market Share by Application (2021-2032)
6 Global Midostaurin Soft Capsules Sales by Region
- 6.1 Global Midostaurin Soft Capsules Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Midostaurin Soft Capsules Sales by Region (2021-2032)
- 6.2.1 Global Midostaurin Soft Capsules Sales by Region (2021-2026)
- 6.2.2 Global Midostaurin Soft Capsules Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Midostaurin Soft Capsules Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Midostaurin Soft Capsules Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Midostaurin Soft Capsules Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Midostaurin Soft Capsules Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Midostaurin Soft Capsules Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Midostaurin Soft Capsules Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Midostaurin Soft Capsules Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Midostaurin Soft Capsules Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Midostaurin Soft Capsules Revenue by Region
- 7.1 Global Midostaurin Soft Capsules Revenue by Region
- 7.1.1 Global Midostaurin Soft Capsules Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Midostaurin Soft Capsules Revenue by Region (2021-2026)
- 7.1.3 Global Midostaurin Soft Capsules Revenue by Region (2027-2032)
- 7.1.4 Global Midostaurin Soft Capsules Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Midostaurin Soft Capsules Revenue (2021-2032)
- 7.2.2 North America Midostaurin Soft Capsules Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Midostaurin Soft Capsules Revenue (2021-2032)
- 7.3.2 Europe Midostaurin Soft Capsules Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Midostaurin Soft Capsules Revenue (2021-2032)
- 7.4.2 Asia-Pacific Midostaurin Soft Capsules Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Midostaurin Soft Capsules Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Midostaurin Soft Capsules Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Dr Reddys Laboratories
- 8.1.1 Dr Reddys Laboratories Company Information
- 8.1.2 Dr Reddys Laboratories Business Overview
- 8.1.3 Dr Reddys Laboratories Midostaurin Soft Capsules Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Dr Reddys Laboratories Midostaurin Soft Capsules Product Portfolio
- 8.1.5 Dr Reddys Laboratories Recent Developments
- 8.2 Glenmark Pharmaceuticals
- 8.2.1 Glenmark Pharmaceuticals Company Information
- 8.2.2 Glenmark Pharmaceuticals Business Overview
- 8.2.3 Glenmark Pharmaceuticals Midostaurin Soft Capsules Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Glenmark Pharmaceuticals Midostaurin Soft Capsules Product Portfolio
- 8.2.5 Glenmark Pharmaceuticals Recent Developments
- 8.3 Zydus
- 8.3.1 Zydus Company Information
- 8.3.2 Zydus Business Overview
- 8.3.3 Zydus Midostaurin Soft Capsules Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Zydus Midostaurin Soft Capsules Product Portfolio
- 8.3.5 Zydus Recent Developments
- 8.4 Novartis
- 8.4.1 Novartis Company Information
- 8.4.2 Novartis Business Overview
- 8.4.3 Novartis Midostaurin Soft Capsules Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Novartis Midostaurin Soft Capsules Product Portfolio
- 8.4.5 Novartis Recent Developments
- 8.5 Teva Pharmaceuticals
- 8.5.1 Teva Pharmaceuticals Company Information
- 8.5.2 Teva Pharmaceuticals Business Overview
- 8.5.3 Teva Pharmaceuticals Midostaurin Soft Capsules Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Teva Pharmaceuticals Midostaurin Soft Capsules Product Portfolio
- 8.5.5 Teva Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Midostaurin Soft Capsules Value Chain Analysis
- 9.1.1 Midostaurin Soft Capsules Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Midostaurin Soft Capsules Production Mode & Process
- 9.2 Midostaurin Soft Capsules Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Midostaurin Soft Capsules Distributors
- 9.2.3 Midostaurin Soft Capsules Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst